Dishman Carbogen Amcis Limited has informed the Exchange regarding a press release dated Jun 06, 2025, titled "Announcement: Company s wholly-owned subsidiary viz. CARBOGEN AMCIS AG has entered into a Co-investment agreement with a long-standing Japan based customer to expand its ADC Manufacturing sites situated at Aarau and Neuland in Switzerland".
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dishman Carbogen Amcis's wholly-owned Swiss subsidiary, CARBOGEN AMCIS AG, has signed a co-investment deal worth over CHF 25 million with a long-standing Japanese customer to expand its antibody-drug conjugate (ADC) manufacturing facilities in Aarau and Neuland, Switzerland. The investment will fund new 850-litre reactors, agitated filter dryers, and supporting infrastructure at both sites, with completion targeted for Q1 and Q3 2027 respectively. The project supports production of a drug linker for a commercial ADC and builds on a similar joint funding deal from April 2021 for the Bubendorf site. CARBOGEN AMCIS is a CDMO serving the pharmaceutical and biopharmaceutical industries with operations across Switzerland, France, the UK, the Netherlands, and China.
This is a positive development, signalling strong demand visibility from a key client and locked-in future revenue for the subsidiary's high-margin ADC services. The capex is largely funded by the customer, limiting balance sheet strain for Dishman while boosting long-term manufacturing capacity and earnings potential.